Journal profile · Pharmacology & Pharmacy
MEDICAL LETTER ON DRUGS AND THERAPEUTICS
ISSN 0025-732X · eISSN 1523-2859 · Medical Letter Inc. · UNITED STATES · Biweekly
MEDICAL LETTER ON DRUGS AND THERAPEUTICS: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 0.4; subscription journal; review 6–12 weeks (community reports); community-reported acceptance: easy; 137 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
MEDICAL LETTER ON DRUGS AND THERAPEUTICS is published by Medical Letter Inc. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Diabetes Treatment and Management, Pharmaceutical studies and practices and Lung Cancer Treatments and Mutations, together about 18.7% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
The Medical Letter, Inc. is committed to providing objective, practical, and timely information on drugs and treatments of common diseases to help our readers make the best decisions for their patients—without the influence of the pharmaceutical industry.
From the journal's Aims & Scope
Research area (LetPub): Pharmacology & Pharmacy
Editor-in-chief Jean-Marie PflommPublisher website
Main research topics OpenAlex counts of recent articles; shares are approximate
- Diabetes Treatment and ManagementMedicine7%
- Pharmaceutical studies and practicesMedicine6%
- Lung Cancer Treatments and MutationsMedicine5.7%
- Respiratory viral infections researchMedicine5.7%
- CAR-T cell therapy researchMedicine5.7%
- SARS-CoV-2 and COVID-19 ResearchMedicine4.8%
- Asthma and respiratory diseasesMedicine4.5%
- Pharmacology and Obesity TreatmentMedicine4.5%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 0.4LetPub ·
- CiteScore 2026-06
- 1LetPub ·
- SJR 2026-06
- 0.26LetPub ·
- SNIP 2026-06
- 0.1LetPub ·
- h-index
- 18LetPub ·
- h-index
- 7OpenAlex ·
- i10-index
- 4OpenAlex ·
- 2-year mean citedness
- 0.53OpenAlex ·
- Self-citation rate
- 36.4%LetPub ·
- Share of gold OA articles
- 0%LetPub ·
Volume
- Articles per year
- 85LetPub ·
Articles by year OpenAlex count · 515 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 91 | 0 | 21 |
| 2025 | 137 | 1 | 56 |
| 2024 | 141 | 0 | 118 |
| 2023 | 146 | 2 | 168 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- EasyLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Subscription journalLetPub
A subscription journal: articles are read by subscription or purchase, and authors usually pay no publication charge.
No source has fee information yet; check the journal's website.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Policy excerpts from the journal's websiteConflicts of interest
- Conflicts of interest
No industry reprints Model summary
does not sell reprints to industry for promotion
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Medical Letter Inc.
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Biweekly
- ISSN
- 0025-732X
- Electronic ISSN
- 1523-2859
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about MEDICAL LETTER ON DRUGS AND THERAPEUTICS
What CAS zone is MEDICAL LETTER ON DRUGS AND THERAPEUTICS in?
In the 2025 upgraded edition of the CAS Journal Ranking, MEDICAL LETTER ON DRUGS AND THERAPEUTICS is in Zone 4 of Medicine, and in Zone 4 of the minor category Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of MEDICAL LETTER ON DRUGS AND THERAPEUTICS?
The latest impact factor listed by LetPub is 0.4; CiteScore 1, h-index 7.
How long does peer review take at MEDICAL LETTER ON DRUGS AND THERAPEUTICS?
Authors report an average review time of 6–12 weeks; the community-reported acceptance is “Easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index MEDICAL LETTER ON DRUGS AND THERAPEUTICS?
According to LetPub and DOAJ records, MEDICAL LETTER ON DRUGS AND THERAPEUTICS is indexed in SCIE and Scopus.
Is MEDICAL LETTER ON DRUGS AND THERAPEUTICS open access, and what is the APC?
MEDICAL LETTER ON DRUGS AND THERAPEUTICS is a subscription journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .